Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First‐Line Treatment in Patients With Metastatic Castration‐Resistant Prostate Cancer: TALAPRO‐2... by Nobuaki Matsubara, Hideaki Miyake, Hiroji Uemura, Atsushi Mizokami, Hiroaki Kikukawa, Takeo Kosaka, Kazuo Nishimura, Motonobu Nakamura, Kazuki Kobayashi, Atsushi Komaru, Yuko Mori, Shigeyuki Toyoizumi, Natsuki Hori, Yoshiko Umeyama, Hirotsugu Uemura

Subjects: “…enzalutamide…”
Get full text

Osteoblast‐Derived ECM1 Promotes Anti‐Androgen Resistance in Bone Metastatic Prostate Cancer by Xinwen Wang, Min Wang, Qijun Lin, Lixin He, Baolin Zhang, Xin Chen, Guanhong Chen, Hong Du, Chuandong Lang, Xinsheng Peng, Yuhu Dai

Subjects: Get full text

Feasibility of enzalutamide on patients with recurrent non-muscle-invasive bladder cancer with marker tumors: phase I study by Takashi Kawahara, Shuya Kandori, Takahiro Kojima, Bryan J. Mathis, Masanobu Shiga, Hiroyuki Nishiyama

Subjects: Get full text

ECM-mimicking hydrogel models of human adipose tissue identify deregulated lipid metabolism in the prostate cancer-adipocyte crosstalk under antiandrogen therapy by Agathe Bessot, Joan Röhl, Maria Emmerich, Anton Klotz, Akhilandeshwari Ravichandran, Christoph Meinert, David Waugh, Jacqui McGovern, Jenni Gunter, Nathalie Bock

Subjects: Get full text

Meta-analysis to evaluate the comparative effectiveness of enzalutamide and abiraterone acetate for first-line treatment of metastatic castration-resistant prostate cancer in real-... by Armen Aprikian, Amit Bahl, Aurelius Omlin, Giulia Baciarello, Abhiroop Chakravarty, Prashanth Kondaparthi, Georgia Gourgioti, Thomas McLean, Alexis Serikoff, Andrew Chilelli

Subjects: “…enzalutamide…”
Get full text

A novel peptide encoded by circSRCAP confers resistance to enzalutamide by inhibiting the ubiquitin-dependent degradation of AR-V7 in castration-resistant prostate cancer by Xiannan Meng, Qingxuan Wu, Chengsong Cao, Wendong Yang, Sufang Chu, Hongjun Guo, Suhua Qi, Jin Bai

Subjects: Get full text